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Abstract
A central assumption in the design and conduct of non-inferiority trials is that the
active-control therapy will have the same degree of effectiveness in the planned noninferiority trial as it had in the prior placebo-controlled trials used to define the noninferiority margin. This is referred to as the ‘constancy’ assumption. If the constancy
assumption fails, the chosen non-inferiority margin is not valid and the study runs
the risk of approving an inferior product or failing to approve a beneficial product.
The constancy assumption cannot be validated in a trial without a placebo arm, and
it is unlikely ever to be met completely. However, it is often the case that there
exist strong, measurable predictors of constancy, such as dosing and adherence, and
such predictors can be used to identify situations where the constancy assumption
will likely fail. Here we propose a method for using measurable predictors of activecontrol effectiveness to specify non-inferiority margins targeted to the planned study
population, and further use these predictors to adapt the non-inferiority margin at the
end of the study. Population-specific margins can help avoid violations of the constancy
assumption, and adaptive margins can help adjust for violations that will inevitably
occur in real clinical trials, while at the same time maintain pre-specified levels of type
I error and power.

1

Introduction

Non-inferiority (NI) trials are designed to determine whether a new therapy is as effective
as, or at least not meaningfully worse than, an existing therapy that was previously approved based on placebo-controlled trials. By comparing the new therapy to the approved
“active-control” therapy, an NI trial can be used to infer whether the new therapy is effective without having to incorporate a placebo-control arm. For this inference to be valid
it must be assumed that the active-control therapy has a similar degree of effectiveness in
the planned NI trial as it had in prior placebo-controlled trials. This is referred to as the
“constancy” assumption. The constancy assumption cannot be validated in a trial without
a placebo arm, and it is unlikely to ever be met completely; however, various strategies can

1

Hosted by The Berkeley Electronic Press

be used to minimize the risk of non-constancy.
A first approach is simply to specify entry criteria designed to enroll participants who
match the participants from the prior trials, and specify in the protocol a dosing amount
and schedule identical to the schedule and dosing used in prior trials. Unfortunately, identical entry criteria can yield very different participant populations, particularly if the new
trial is conducted in a difference setting, city or country. Also, although it may be simple
to prescribe a specific dosing schedule, actual dosing may vary dramatically depending on
adherence.
Prior articles have suggested modifications to the non-inferiority margin when there
exists evidence of constancy failure. Everson-Stewart [1] proposed a model for assessing
constancy based on heterogeneous effectiveness in population subgroups, and recommended
tightening the margin, or moving to a superiority design, if constancy is violated. This
approach has an important limitation in that it only allows for tightening the margin, never
relaxing the margin, which fails to account for situations where active-control effectiveness
is higher than planned. Nie and Soon [2] developed a regression-model approach for identifying potential non-constancy, and use population characteristics to define a non-inferiority
margin appropriate for the enrolled study participants. They did not, however, demonstrate
whether modifying the margin could improve, or harm, the trial’s operating characteristics.
Although our modeling approach is somewhat different from the one proposed by Nie
and Soon, our objective is essentially to extend Nie and Soon’s idea of an adjusted noninferiority margin to the planning, monitoring, and analysis phases of a non-inferiority trial.
In addition to modeling population characteristics, the proposed method incorporates dynamic features of the trial, such as dosing and adherence, which can only be measured
during the trial or after the trial is complete. We propose several methods for adapting
the non-inferiority margin, and evaluate how each method can influence operating characteristics such as Type-I error, power, and expected sample size. An example trial of HIV
pre-exposure prophylaxis (PrEP) is used for illustration.

2

Sources of Non-Constancy and Defining the NI Margin

Non-constancy can occur for a variety of reasons, including differences in participant characteristics, differences in dosing or adherence, changes in background supportive care, or
actual declines in biological benefit, for example due to increased resistance to an antibiotic. Many potential sources of non-constancy may be unobservable, but the associations
between certain observable participant characteristics and the effectiveness of a therapy are
sometimes known. These factors can be divided into two categories: (1) fixed population
attributes such as race, gender, and age that do not change appreciably during a trial and
can be measured at baseline, and (2) dynamic features, such as dosing and drug adherence,
that could change during the course of a trial and cannot be assessed until the trial is complete.
An important aspect of dynamic features is that not only can they differ over time, they
2
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can also differ between treatment arms. For example, in an HIV-prevention trial of longacting injectable pre-exposure prophylaxis (PrEP) compared to daily oral pill-based PrEP,
participants in the injectable arm are likely to have high adherence, assuming they receive
directly observed injections, while participants in the oral arm may have mixed adherence,
depending on how well they take the pills. This is true even in a double-blind, doubledummy trial (participants receiving active injections and placebo pills, versus participants
receiving active pills and placebo injections) because adherence to the oral pills will only
influence drug concentrations in participants receiving the active, oral pills.
To protect against falsely declaring non-inferiority (inflated type I error) if the active
control is not as effective as in prior trials, NI margins are often chosen to be conservative
(i.e. less likely to produce a significant result). Defining the non-inferiority margin typically
involves estimating the effect of an active-contol therapy based on prior placebo-controlled
trials, and choosing a non-inferiority margin that conserves some proportion ρ of the activecontrol effect [3]. For example, consider a series of two arm trials comparing the activeˆ C/P be the estimated relative risk based on a
control therapy C to placebo P , and let RR
meta analysis. The non-inferiority margin δ ∗ can be defined, conservatively, to preserve at
least (100 × ρ)% of the active-control benefit by setting
d P/C ))1−ρ
δ ∗ = (LCL95 (RR

(1)

ˆ P/C = RR
ˆ −1
where LCL95 is the lower limit of the 95% confidence interval and RR
C/P .
The lower confidence limit for the active-control effect can be thought of as the ‘assured
effect’, i.e. evidence from prior trials rules out a smaller effect, but does not assure anything
larger. Using the LCL95 as the estimated active-control effect acknowledges the uncertainty
associated with the meta-analytic estimate and therefore provides a degree of protection
against non-constancy. Values for ρ can range between 0 and 1, where choosing ρ = 0
gives a margin that does not preserve any benefit of C but assures that the experimental
therapy E is at least better than placebo, and choosing ρ = 1 gives a margin of 1.0 which
is equivalent to requiring superiority of E over C. The value for ρ is most often taken to
be 0.50, yielding a margin that preserves at least 50% of the benefit provided by C (on the
log relative risk scale). If the results of a non-inferiority trial comparing an E to the active
control satisfy
d E/C ) < δ ∗
U CL95 (RR

(2)

where U CL95 is the upper limit on the 95% confidence interval, then the trial results are
consistent with non-inferiority.
The meta-analysis-based margin δ ∗ in (1) effectively assumes that the active-control effect in the planned trial will correspond to the average effect observed in the prior placebocontrolled trials, and ignores attributes and dynamic features of the planned study population that predict effectiveness (i.e. effect modifiers). Post hoc subgroup analyses are
regularly performed on clinical-trial data to identify correlates of effectivess. Although such
analyses can be informative in setting a better margin, subgroup analyses are generally
underpowered and exploratory in nature. In addition, analyses of effectiveness based on
post-randomization factors such as drug adherence do not benefit from the protection of
randomization and therefore may not yield valid results. In the next section we suggest a
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strategy than could more reliably identify effect modifiers.

3

Trial-level variables, meta-regression, and populationspecific NI margins

Rather than relying on subgroup analyses from individual trials, effect modifiers may be
identified by using meta-analysis regression to combine results across multiple studies. The
meta-analysis approach can improve power and precision for estimating effect modification
in important demographic and clinical subgroups [4]. Improved power results from the increased sample sizes achieved by combining data from multiple trials. Second, by comparing
post-randomization effects across studies, rather than within studies, the meta-analysis approach can reduce the potential for confounding. While it is well recognized that cross-trial
comparisons may be influenced by ecological bias [5], the potential for confounding by postrandomization variables is a more serious concern.
For example, within-study estimation of the association between drug adherence and
effectiveness could easily be confounded by medication side effects. That is, if adherence
is influenced by the treatment, then the estimation of treatment effects among adherers
and non-adherers would no longer rely on randomized comparisons. On the other hand, if
multiple randomized, blinded, controlled trials with different levels of adherence show an
association between adherence and effectiveness, we know that estimation of within-study
treatment effects is protected by randomization and unconfounded by medication side effects. By treating dynamic features such as drug adherence as trial-level variables in a
meta-regression model, dynamic effect modifiers can be identified and estimated without
the usual hazards associated with analysis of post-randomization subgroups.
To estimate the size and importance of potential effect modifiers, mixed-effects meta
analysis can be extended to a regression model that includes study-level, fixed-effects covariates [6] as follows:
log(RRj ) = β0 + β 1 xj + β 2 z j + bj + εj

(3)

where xj are population attributes, z j are dynamic features, bj are the study-specific random effects with bj ∼ N (0, τ 2 ) and τ 2 the between study variance, and εj are error terms
corresponding to study-specific effect-size estimates with εj ∼ N (0, σj2 ). Fixed-effect parameter estimates βˆ0 , βˆ1 , and βˆ2 can then be used to estimate effectiveness in a new study
with anticipated attributes xA and features z A , as
d P/C (xA , z A ) = exp(βˆ0 + βˆ1 xA + βˆ2 z A ).
RR

(4)

A population-specific NI margin can then be computed based on the lower confidence limit
of the 95% confidenc limit of the regression model estimate, preserving at least the fraction
ρ of the active control benefit, by setting
d P/C (xA , z A )))1−ρ .
δ(xA , z A , ρ) = (LCL95 (RR

(5)

For illustration we consider a meta-analysis regression using results from randomized,
placebo-controlled trials of oral PrEP. Adherence to oral PrEP is considered to be a strong
4
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dynamic effect modifier, and there is some evidence that oral PrEP may be less effective
in women, so both a dynamic and baseline factor are included in the model. Results from
seven major randomized trials are included in the analysis [7; 8; 9; 10; 11; 12; 13], giving
the estimated regression equation
d P/C (sex, adherence) = exp(0.7520 − 0.1058 × sex − 2.276 × adherence)
RR

(6)

where sex is an indicator variable of sex at birth with 1 = male, and adherence is a measure between zero and one of the proportion of participants with detectable plasma levels
of PrEP. Figure 1 shows a scatterplot of the trial results as a function of adherence, divided
by sex. The fitted regression line for men, along with confidence bounds, are shown. For a
planned study in men, the lower confidence limits in Figure 1 would be used as the basis
for computing the NI margin. The lower confidence limit is used as a conservative estimate
for effectiveness in the regression setting because even though observable factors may be
accounted for, unobservable or unrecognized sources of non-constancy cannot be ruled out.
For a hypothetical trial enrolling men, a range of possible margins derived from this
regression equation are shown in Table 1. An essential result is that when projected adherence falls below approximately 40%, the lower confidence limit on projected effectiveness
falls below 1.0, indicating that there is not strong evidence for effectiveness, and that a
superiority trial is recommended. (A non-inferiority trial with a margin of 1.0 is equivalent
to a superiority trial.) This suggests that in general the meta-regression model may be used
not only to set the NI margin, but also to determine under what circumstances an NI trial
is appropriate.
Adherence
0.40
0.50
0.60
0.70
0.80

Effectiveness
<1.0
1.17
1.50
1.89
2.30

NI Margin
1.0
1.08
1.23
1.37
1.52

Table 1: Predicted oral-PrEP effectiveness in men as a function of adherence, and suggested
NI margins that preserve at least 50% of the benefit (ρ = 0.5).

4

Non-constancy, Type I Error and Power.

The study population in a clinical trial often is not identical to the populations in the prior
placebo-controlled trials used for identifying the NI margin. For an intervention with substantial effect modifiers, even if a population-specific approach is used to select the margin,
population attributes and dynamic features in the new trial may not match the values used
in the planning phase. If these values are substantially different from the planning phase,
there is a risk that the constancy assumption will fail and the selected NI margin will not
be valid, in which case the trial runs the risk of declaring support for a product that doesn’t
work (type I error), or failing to support a product that does work (type II error). In
5
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the context of a non-inferiority trial, a product that ‘works’ is one that provides a similar
amount of benefit to the active control, where the active-control benefit is defined in relation
to placebo, and a product that does not ‘work’ is one that provides signifantly less benefit
than the active control, or provides no benefit at all (i.e. is equivalent to placebo, or causes
harm).
To illustrate, consider a trial that is designed under the assumed values x = xA and
z = z A , and using corresponding NI margin δ(xA , z A , ρ) as in (5). Unlike a superiority trial
where the goal is to rule out H0 : RR = 1.0, in a non-inferiority trial the goal is to rule out
the NI margin, leading to the hypotheses:
H0 : RRE/C = δ(xA , z A , ρ)

(7)

H1 : RRE/C < δ(xA , z A , ρ),

where δ() will typically be larger than 1.0. Re-expressing these hypotheses in terms of incidence rates helps isolate the impact of non-constancy. The relative effectiveness RRE/C
A
can be written as λE /λA
C , where λE is the incidence rate in E, and λC is the incidence rate
A
A
in C when x = x and z = z . The null hypothesis in (7) can then be written as

A
A
H0 : λE = λ0E = λA
C δ(x , z , ρ),

(8)

λ0E

where
is defined to be the highest allowable incidence under E that would be considered
clinically acceptable.
The specific alternative hypothesis used to compute sample size and power is often based
on the desire to reject H0 if E has an effect similar to C, that is, if H1 : RRE/C = 1.0.
If there is reason to expect that E may outperform C then the study may be powered to
establish a somewhat stronger effect, say H1 : RRE/C = ξ, where ξ ∈ [0, 1]. The alternative
hypothesis is then expressed in terms of incidence rates as
H1 : λE = λ1E = λA
C ξ.

(9)

Note that since an NI trial is designed to rule out the margin, not equality, the trial is
powered to detect an effect size (ratio of the alternative to the null) equal to ξ/δ(xA , z A , ρ).
If the true study population characteristics turn out be xT 6= xA and z T 6= z A such that
RRC/P (xT , z T ) 6= RRC/P (xA , z A ) then the planned margin δ(xA , z A , ρ) will be incorrect
and the study will not retain desired levels of type I error and power. By expressing RRE/C
in terms of incidence rates, and using the fact that λTC = λP RRC/P (xT , z T ), where λP
is incidence in a hypothetical placebo arm, type I error and power can be expressed as a
function of RRC/P (xT , z T ):


i
λE
A
A
0
<
δ(x
,
z
,
ρ)|λ
=
λ
E
E
λP RRC/P (xT , z T )
h


i
λE
A
A
1
Power = P U CL95
<
δ(x
,
z
,
ρ)|λ
=
λ
E
E .
λP RRC/P (xT , z T )

h

P [Type I error] = P U CL95

(10)
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Error rates for an example trial are plotted in Figure (2) as a function of the (hypothetical) percent risk reduction provided by C (versus placebo) in the true study population, or
(1 − RRC/P (xT , z T )) × 100. If C is more effective than planned, E will not look as good in
comparison, and the type II error rate will be high (i.e. the trial will have low power.) If C
is less effective than planned, E will appear better in comparison to C, and the chances of a
false-positive result will increase. It is clear that fairly small deviations from constancy can
have a substantial impact on the probability of making a false conclusion. For instance if C
is 60% effective instead of the planned 50%, the type II error probability increases from 10%
to 48% (i.e. power drops from 90% to 52%). Likewise if C is only 40% effective, the type I error probability elevates from 2.5% to 16%. To reduce these error probabilities we propose an
adaptive NI margin approach that makes use of observable study population characteristics.

5

Adaptive NI Margins

Although an NI margin must be specified in order to plan an NI trial, the margin used for
planning may not always be the appropriate gauge to judge whether the new product is
truly effective. As demonstrated in the previous section, using the wrong NI margin at the
analysis stage can be detrimental to the operating characteristics of a trial, and the trial
may fail to ensure that the experimental therapy provides sufficient benefit over placebo to
warrant approval. In order to make certain that an NI trial will only support a therapy that
meets a pre-specified level of effectiveness, we propose a method for adapting the planned
margin that is designed to accomodate observed non-constancy.
In the presence of signifcant effect modifiers, we suggest an adaptive margin, where we
pre-specify an equation for updating the non-inferiority margin at the end of the study
based on meta-analysis regression, such as in (4). The method for updating incorportates
pre-specified, observable characteristics of the trial population, including both baseline characteristics and dynamic features that can be measured during or after the trial. We use the
terms xT and z T to refer to the observed, or ‘true’, values of the baseline characteristics
and dynamic features, respectively, of the study population. A pre-specified level of benefit
over placebo, which we refer to as ‘absolute effectiveneses’, (or an equation for absolute
effectiveness,) is also required and is discussed below.
There are a number of possible ways to define an adaptive NI margin, and the rationale
for each choice is slightly different. Determining the most appropriate strategy for adapting
the margin will depend on the goals of the trial, the factors that influence non-constancy,
and the investigators’ perspective. As we describe the various methods for adjusting the
margin below, we also discuss the rationale for each choice.
To facilitate the calculation of adaptive margins, it is useful to define the NI margin
in relation to the absolute effectiveness the experimental therapy is required to provide
with respect to a (hypothetical, unobserved) placebo. This is precisely the way NI margins
are typically calculated, but here we explicitly define the margin in terms of the required
experimental-therapy-versus-placebo relative risk, RRE/P , which we call ∆. Specifically, the
adaptive margin, δ a , is expressed as a function of both ∆ and the estimated active-control
effect:

7
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d P/C (xT , z T )),
δ a = ∆ × LCL95 (RR

(11)

Recall that the active-control effect takes the somewhat counterintuitive form of the placeboversus-control relative risk (i.e. a measure of how much worse the placebo performs as compared to the active control therapy.) This results in a margin which defines how much worse
the experimental therapy can be as compared to the control therapy. And again, the lower
confidence limit of the estimated active-control effect (the ‘assured effect’) is used in order
to account for unmeasured factors that may influence constancy.
For example, if we wish to ensure that the experimental therapy provides at least 25%
risk reduction as compared to placebo, we would specify ∆ = 0.75. Suppose also that,
based on observed study population characteristics, the estimated effect of the active control (placebo-versus-control relative risk) is 2.0 with lower confidence limit 1.8. Our adaptive
margin would then be defined as δ = 0.75 × 1.8 = 1.35. Provided that the upper confidence
limit of the experimental-versus-control relative risk falls below 1.35, we are assured that
the experimental therapy is at least 25% more effective than placebo.
d P/C (xT , z T )) based
The general approach for computing δ a is to compute LCL95 (RR
on measured values for x and z, and then multply by ∆. The value of ∆ may be fixed in
advance, or may depend on xT and z T , as described below. It is clear from (11) that even
if ∆ is fixed, δ a is flexible and depends on the observed study population.
There are two general strategies for specifying ∆, one that requires a pre-specified level
of absolute effectiveness, and the other that provides flexibility depending on how well the
active control therapy works in the study population.
For method one, a fixed, pre-specified level of benefit ∆ is chosen, which can be defined as
either (a) the amount of benefit over placebo that was used to define the meta-analysis-based
margin, or (b) an investigator-defined minimal clinically important difference (MCID). For
example, if the pre-planned margin is the meta-regression-based margin δ(xA , z A , ρ) described in (5), we would define the planned value for ∆ as

d P/C (xA , z A ))−1
∆P lan = δ(xA , z A , ρ) × LCL95 (RR
d P/C (xA , z A )))1−ρ × LCL95 (RR
d P/C (xA , z A ))−1
= (LCL95 (RR
A

−ρ

A

d P/C (x , z )))
= (LCL95 (RR

(12)

,

which uses the planned values xA and z A in relation (11). If xT = xA and z T = z A then
δ a = δ(xA , z A , ρ).
The rationale for this choice may be that investigators believe the original parameters
used to plan the trial provide a margin that would, in a positive trial, establish a reasonable
level of clinical effectiveness, and that deviations in participant characterisitics or behavior
should have no bearing on the minimum required benefit. Note that the planned margin
may be – and typically is – based on a simple, unconditional meta-analysis estimate of
d P/C )−ρ , where RR
d P/C is derived from a
RRP/C . In this situation ∆P lan = (LCL95 (RR
8
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standard (non-regression-based) meta analysis of prior placebo-controlled trials.
Similarly, an NI trial might have been planned based on a fixed MCID, which may be
based on investigator consensus, expert opinion or both. For example, it might be determined that regardless of study population characteristics, it is essential that the experimental
product provide a risk of reduction of at least 10% (RRE/P = 0.90) over what would be
expected with placebo. In this case ∆ would be defined as
∆M CID = RRM CID = 0.90,

(13)

where RRM CID is the risk reduction corresponding to the pre-specified MCID. Since relative risks increase in value as benefit decreases, RRM CID is actually the maximum allowable
relative risk. Note that this approach could also be used in the planning phase when defining
the original margin.
The second strategy for specifying ∆ allows the required level of effectiveness to vary
depending on the estimated effectiveness of the active-control therapy in the current trial.
This can be done by defining ∆ as a proportion of the benefit provided by the active-control
therapy in the observed study population. For instance, assume that study population characteristics xT are observable at baseline, and let z T be dynamic features assessed during
followup. Then define ∆Estimated based on the level of active-control effectiveness, as follows:
d P/C (xT , z T )))−ρ ,
∆Estimated = (LCL95 (RR

(14)

ˆ P/C (xT , z T ) is computed using the meta-analysis equation (4), and ρ is the conwhere RR
served proportion of the active-control treatment effect. This gives the adaptive margin:
d P/C (xT , z T ))1−ρ ,
δ a = LCL95 (RR

(15)

Alternatively, ∆ may be defined by selecting the more stringent of the two choices
∆M CID or ∆Estimated , which is accomplished by choosing the minimum:
∆M in = Min(∆M CID , ∆Estimated )
d P/C (xT , z T )))−ρ )
= Min(RRM CID , (LCL95 (RR

(16)

This will typically mean using ∆Estimated when the active-control effect is large (i.e. substantially more than the MCID), and using ∆M CID when the effect of the active control
is estimated to be relatively small. Using this method prevents the level of required effectiveness from diminishing too far in a study population where the active-control therapy is
thought to be not working well, for example due to low adherence.
Using a flexible value for ∆ may be desirable when the control therapy has different
levels of effectiveness in different populations. For example, assume that the control treatment has been shown to be more effective in adults that in adolescents, and that, despite
efforts to recruit adults, the study population turned out to be mostly adolescents. Because
the control treatment is expected to be less effective in the observed study population, it
may be reasonable to reduce the requirements for the experimental therepy. By using the
planned value for ρ, we can increase the value of ∆ using equation (14), thus increasing the
9
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NI margin δ to a level that preserves the desired proportion of the active-control benefit in
a mostly adolescent population.

6

Adapting the Statistical Hypotheses

Once the adapted margin δ a has been specified, this margin becomes the null hypothesis for
statistical inference. Although the nominal value of the null hypothesis will have changed
from the planning stage, the adapted null still corresponds to the pre-planned amount of
benefit that the experimental therapy is required to provide. When control-therapy effectiveness is variable, and the null hypothesis is expressed in relation to the control therapy,
the nominal value of the null hypothesis must change in order to determine whether the
experimental treatment produces the required level ∆ of absolute effectiveness over placebo.
Note that if a trial is planned based on (5), the analysis margin (and hence the null hypothesis) will be the same as the planning margin if the constancy assumption is met, i.e.
if xT = xA and z T = z A .
Just as the nominal value of the null hypothesis can change under an adaptive NI margin strategy, so too can the nominal value of the alternative hypothesis. As discussed in
section 4, in an NI trial the alternative hypothesis is expressed as a relative risk in relation
to the active control, but the effect size that defines power and sample size depends on both
the alternative hypothesis and the planned NI margin. We define the effect size Ω as the
ratio ξ/δ, which represents the difference between the null and alternative hypotheses onthe
relative risk scale. For example, if the alternative hypothesis is ξ = 0.90 and the NI margin
δ is 1.1, the effect size used to compute power and sample size is Ω = ξ/δ = 0.82.
Because active-control effectiveness – and hence the NI margin – is a moving target
under non-constancy, it is useful to anchor the alternative hypothesis to the hypothetical
placebo arm, just as we did for the null. Let ΩP lan be defined as the target effect size of
the experimental treatment over placebo, defined as
d P/C (xA , z A )).
ΩP lan = ξ/LCL95 (RR

(17)

The effect size ΩP lan can be thought of as the ‘absolute’ target benefit of the experimental
product, as opposed to the relative benefit over the active-control therapy, and this target
remains fixed even when the active-control effect changes as a result of non-constancy. The
planned alternative hypothesis can be expressed as a function of ΩP lan as
d P/C (xA , z A )),
ξ = ΩP lan × LCL95 (RR
T

(18)

T

and once the values for x and z have been observed we can adjust the nominal value of ξ
to reflect the pre-planned target effect. Using the observed study population characteristics
gives the following adaptive alternative hypothesis:
d P/C (xT , z T )).
ξ a = ΩP lan × LCL95 (RR

(19)

Although the nominal value of ξ will have changed, by fixing Ω we preserve the initial,
planned target effect of the experimental treatment over placebo.

10
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There are circumstances in which an investigator may not want to change the alternative
hypothesis, even when faced with non-constancy. For example, a common non-inferiority
alternative hypothesis is ξ = RRE/C = 1.0, meaning that trial is designed to establish noninferiority in the situation where experimental and active-control treatments are equally
effective. Regardless of whether the study population turns out as planned, investigators
may want to ensure that the trial is powered to establish non-inferiority when the experimental treatment is equivalent to the control treatment (often the standard of care) in the
study population.

7

Type-I Error and Power

With the adapted null and alternative hypotheses established, we now reassess the Type-I
error probability and power. In contrast to the scenario described in section 4, after the
NI margin and null hypothesis have been adjusted to reflect the observed study population,
there is no longer a mismatch between the observed relative risk under the null (based on
xT and z T ) and the unadjusted NI margin (based on xA and z A ), and hence no inflation
or reduction in Type-I error.
Statistical power will depend on sample size and the ratio of the adjusted alternative and
null hypotheses, i.e. the adjusted effect size. Provided that this ratio does not change, power
will be not be affected. For example, if the NI margin is planned using the meta-analysis
regression in (5), the planned effect size can be written as the ratio of (18) and (5) as follows,

d P/C (xA , z A ))
ΩP lan × LCL95 (RR
ξ
=
d P/C (xA , z A )))1−ρ
δ
(LCL95 (RR
A

A

(20)
ρ

d P/C (x , z ))) .
= ΩP lan × (LCL95 (RR
If δ is computed using the pre-specified value ∆P lan , the adjusted effect size does not change:
d P/C (xT , z T ))
ΩP lan × LCL95 (RR
ξa
=
d P/C (xT , z T ))
δa
∆P lan × LCL95 (RR
ΩP lan
=
d P/C (xA , z A )))−ρ
(LCL95 (RR

(21)

d P/C (xA , z A )))ρ .
= ΩP lan × (LCL95 (RR
In other words, if the null and alternative hypotheses are adjusted by using the pre-specified
values for ΩP lan and ∆P lan , the effect size ratio remains the same, and there is no loss or
gain in power. However, if the minimum required benefit ∆ is allowed to vary depending
on observed population characteristics, the effect size will no longer remain constant. Using
estimated-effectiveness to define ∆ as in (14), the adjusted effect becomes
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d P/C (xT , z T ))
ΩP lan × LCL95 (RR
ξa
=
d P/C (xT , z T ))
δa
∆Estimated × LCL95 (RR

(22)

d P/C (xT , z T )))ρ ,
= ΩP lan × (LCL95 (RR
which is a function of observed population characteristics. This means that if the control
therapy is observed to be more effective than planned, the effect size, and consequently the
power, will be higher than planned. On the other hand, if the control therapy is estimated
to be worse than planned, the effect size will be smaller than planned and power will be less
than planned.
Similarly, if the null hypothesis is adjusted but the alternative hypothesis remains constant at, for example, ξ = 1.0, the effect size, and hence power, will vary depending on the
adjusted null, following the equation
1
ξ
=
d
δa
∆ × LCL95 (RRP/C (xT , z T ))

(23)

where ∆ could be ∆P lan , ∆Adjusted , ∆M CID , or ∆M in . In this case the effect size is just
the inverse of the non-inferiority margin. Stronger observed effects in the control arm (i.e.
larger values for placebo-versus-control relative risk) will imply larger effect sizes (smaller
absolute value of the relative risk) and hence higher power. Conversely, weaker than expected effects in the control arm would yield smaller effect sizes and reduced power. This is
intuitive, since if the two interventions are equally effective, it is more difficult to establish
non-inferiority using a narrower margin.

8

Examples

In trials with a fixed, pre-planned number of endpoint events, statistical power will depend
directly on the ratio of the adjusted alternative and null hypotheses, as determined at the
end of the trial. As described in previous sections, there are a variety of choices for adjusting the statistical hypotheses, and hence a number of possible combinations of adjusted
null and adjusted alternatives. In the following we consider three distinct scenarios that
represent realistic options for evaluating a new HIV prevention intervention. The planned
study population has 60% adherence to the active-control drug, and is 50% female.

1. Preserve Planned Benefit – In this scenario the investigators wish to ensure that the
experimental intervention provides a pre-planned level of benefit over placebo, ∆P lan ,
based on preserving 50% of the active control benefit (ρ = 0.5), and wish to power
the trial based on the alternative hypothesis that the experimental intervention has a
specific amount of benefit over placebo, ΩP lan , corresponding to 20% risk reduction
(ξ = 0.80) at the planned covariate levels. The study team believes that the primary
source of non-constancy is likely to be variable adherence to the active-control drug.
Since the primary objective of the trial is to assess biological efficacy, investigators
wish to minimize the impact of unpredictable drug-adherence on the study outcome.
12
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2. Preserve Proportional Benefit – In this scenario the investigators are not sure how well
the active-control therapy will work in the study population, but wish to ensure that
the experimental therapy preserves at least half of the benefit that the active-control
therapy can provide in whatever population is recruited (ρ = 0.5). To this end they
will use ∆Estimated , and with the hope that the new intervention will be about 10%
better than the control intervention in the study population (whatever its composition
might be), they will use the fixed alternative ξ = 0.90.
3. Preserve Proportional Benefit and MCID – This is is similar to scenario 2 except
that the investigators wish to place a limit on how flexible the adaptive margin can
be. There is some concern that the control therapy may perform so poorly in the
study population as to be little better than placebo, and the study team wishes to
assure that the experimental therapy provide at least 10% benefit over placebo, even
if the active-control effectiveness is very low. For this purpose they use ∆M in =
M in(∆Estimated , 0.90). The alternative hypothesis is again fixed at ξ = 0.90.
Figure 3 shows power as a function of observed effectiveness (vs placebo) for each of the
three scenarios. Sample sizes for each scenario are computed based on the planned study
population composition (60% adherence and 50% female), yielding approximately 49% effectiveness, and hence it is at that point that power is always exactly 90% for all scenarios.
Scenario 1 requires a sample size of 204 events to achieve 90% power and a type-I
error rate of 2.5%. The adjusted null and alternative hypotheses are based on the pred P/C (x = 0.5, z = 0.6))−0.5 = 0.79 and ΩP lan =
planned values for ∆P lan = LCL95 (RR
d P/C (x = 0.5, z = 0.6)) = 0.50. As per equation (21), regardless of the degree
0.8/LCL95 (RR
of non-constancy, the adjusted effect size does not change from the planned effect size,
ΩP lan
ξ
ξa
=
= = 0.50/0.79 = 0.63,
δa
∆P lan
δ

(24)

and there is no loss of power (solid line, Figure 3).
Scenarios 2 and 3 both have a planned sample size of 371 events. In scenario 2 the
adjusted null depends on the observed values xT and z T , while the alternative hypothesis
remains fixed at 0.90, yielding an effect size that depends on the observed values,
ξa
ξ
d P/C (xT , z T ))0.5 ,
(25)
= a = 0.90/LCL95 (RR
a
δ
δ
and hence lower levels of active-control effectiveness lead to smaller effect sizes and loss of
power (dashed line, Figure 3).
Senario 3 mimics scenario 2 until active-control effectiveness drops to the point where
∆Estimated becomes larger than 0.90, at which point the effect size drops as a function of
d P/C (xT , z T )), (as opposed to a function of the square root of the LCL95 as in
LCL95 (RR
(25)), as
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ξ
ξa
= a
a
δ
δ
d P/C (xT , z T )))
= 0.90/(RRM CID × LCL95 (RR

(26)

d P/C (xT , z T )))
= 0.90/(0.90 × LCL95 (RR
d P/C (xT , z T ))
= 1/LCL95 (RR
and hence power drops more rapidly as effectiveness drops (dotted line, Figure 3) below approximately 33%. In both scenarios 2 and 3 power becomes inflated for higher-than-planned
levels of active-control effectiveness due to larger effect sizes in combination with constant
sample sizes.

9

Dynamic features and sampling variation

It will not always be possible to measure dynamic features completely and accurately. Labbased drug adherence assessment, for example, requires costly, regular collection and testing
of samples. A more efficient approach may be to sample a random subset of participants,
at a random set of time points, and generate an estimate of adherence rates. To compute
the adapted margin, a sample-based estimate ẑ T may be substituted into (11) in place of
z T . The degree to which sampling variation may influence the margin depends on both the
estimated regression coefficients in (4) and the sampling distribution of z T . Potential bias
introduced by sampling can be quantified by

T

T

δ(x , z , ρ) −

Z

δ(xT , ẑ T , ρ)f (ẑ T )

(27)

where f () is the sampling distribution of ẑ T and δ() is defined as in equation (5). The true
value of z T will generally not be known, but sample sizes for ẑ T should be chosen to provide
precise estimates of z T and minimize potential bias.

10

Discussion

Specifying non-inferiority margins can be a somewhat subjective process, and the validy of
these margins relies heavily on the assumption of constancy. In clinical-trial settings with
known effect modifiers, we have shown that meta-analysis regression can provide objective,
population-specific margins for planned trials, and thus reduce the chances and degree of
constancy violation. In addition, once a trial is complete, the same meta-analysis regression
model can be used to adapt the end-of-study margin according to observed effect modifiers
in the study population, thereby preserving planned levels of Type-I error and power.
Adaptive margins depend on adapted statistical hypotheses, and careful consideration
must be given to how the null and alternative hypotheses should be updated. Certain
choices for updating the hypotheses, however logical and reasonable, will result in low (or
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high) power due to sample sizes that do not correspond to the adapted effect size. As illustrated in examples 2 and 3 above, if active-control effectiveness is less than planned, and
the amount of benefit (∆) required by the adapted NI margin is allowed to vary depending
of estimated effectiveness, power will be less than planned. This does not imply that such
choices for ∆ are incorrect - such decisions should be pre-specified based on sound clinical
judgement - but the potential for reduced power is something investigators should be aware
of.
A key element of our approach is that NI-margin adaptation does not depend on the observed effect size. Meta-regression parameters are estimated prior to starting the new trial,
and depend entirely on efficacy data which is external to the trial. The end-of-study margin
depends only on observed effect modifiers in the new trial, and, to avoid the potential for
bias, should be computed in the absence of any knowledge of the observed effect size. It may
be reasonable to update the meta-regression with data from external trials that conclude
during the conduct of the new trial, but the decision to update the model should also be
pre-specified.
Our meta-analysis regression method is an important extension of Nie and Soon’s approach [2] in that it allows for the inclusion of post-randomization dynamic features, which
in some settings may be the most influential effect modifiers. In trials of HIV PrEP in
high-risk populations, for example, the importance of medication adherence substantially
outweighs any known effect modifier that could be measured at baseline. In fact, for any
medication controlled by the participant, adherence may be the most important effect modifier.
Rohmel and Kieser [14] address the idea of “variable margins” which have been proposed
as way to construct more reasonable NI margins for binary-endpoint trials when failure rates
in the active-control arm are substantially different than expected. The variable-margin approach allows the end-of-study margin to depend on observed failure rates, and when these
rates are lower than a preset threshold, the margin switches from a difference-in-proportions
scale to the odds-ratio scale. Although changing the scale provides some flexibility in the
face on non-constancy, unlike the meta-analysis approach it does not address the question
of how to define an appropriately sized margin based on observed levels of active-control
effectiveness.
The choice of endpoint-assessment scale is nevertheless important. Although our development of the adaptive NI margin approach is limited to the relative risk scale, the same
approach can be used for risk differences by applying the log transformation to (5), so that
the conserved proportion ρ becomes a multiplier on a risk difference instead of an exponent
on a risk ratio. The required benefit ∆ and target benefit Ω would then become additive
differences instead of multipliers. In applications where event rates are fairly high (a threshold 20% is often used in the variable-margin approach) the risk-difference scale may be more
intuitive and useful.
Meta-analysis based adaptive NI margins have important limitations. First, metaanalysis results are only as good as the trials upon which they are based, and it is not
always the case that multiple, high-quality trials are available to analyze. Particularly for
meta-analysis regression, multiple trials with accurate measures of important effect modi-
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fiers are necessary to achieve a reliable regression model. While some fields of study are
rich with existing, high-quality trial data, others are not. Also, critical effect modifiers such
as adherence can be measured in very different ways, yielding different results, for example
self-reported drug adherence has been shown to be consistently and significantly higher than
lab-based adherence measures [11; 10]. Unless parallel measures are used across studies, the
validity of meta-regression model parameters is questionable.
Similarly, assessment of effect modifiers in the new trial must be consistent with the
prior studies used to construct the margin. If measurement is not consistent, regressionbased estimates of active-control effectiveness are unlikely to be accurate, in which case
the adapted NI margin will not result in the desired trial characteristics. In addition, if
measurement methods are not clearly pre-specified, the door may be open for inappropriate
manipulation of the NI margin. For example, if it is known that higher measured adherence
corresponds to higher effectiveness, one need only choose an inflated adherence measure,
such as self-report, to increase the estimated active-control effect and relax the NI margin,
thus making drug approval more likely.
Relying on on between-trial effect-modifier estimates does not come without risks. Unmeasured differences in study populations can introduce ecological bias [5], and the evaluation of gender as an effect modifier in oral PrEP trials represents a classic example. If
drug adherence were not included in the meta-regression model, it would likely appear that
oral PrEP is much less effective in women than in men. This result, however, would be due
to the fact the in several large PrEP trials in women, adherence was very low, whereas in
most trials that include men, adherence was moderate or high (Figure 1). It is therefore
important to use caution when using trial-level data to evaluate effect modifiers, and if postrandomization factors are not included in the model, consider using individial participant
data as proposed by Hua et al. [5].
Sampling error may also introduce bias to an adapted NI margin. In situations where
it is difficult to obtain sufficiently precise estimates of z T , the potential for bias may be
higher. We would suggest assessing the potential for bias by evaluating (27) using a variety
of reasonable values for xT and f (). A sampling plan should select a random subset of
participants, and also, if appropriate, consider and random subset of time points during the
trial in order to account for temporal trends.
Even if effect modifiers could be measured perfectly, it is important to remember that
it is always possible that there are unmeasured effect modifiers. If non-constancy results
from factors that cannot be measured or have otherwise not been included in the metaregression, the adaptive margin will not correct for these unmeasured factors. In the study
of HIV prevention, for instance, measuring exposure to the HIV virus can be challenging. In
a population where sexual contact is the primary form of transmission, it is often not possible to determine whether an individual has engaged in unprotected sex, and if so, whether
their sex partner was HIV infected. If exposure to HIV is substantially less than expected,
and hence HIV incidence is very low, active-control effectiveness may be significantly lower
than is predicted by the model [15].
Meta-analysis regression methods offer a way to define NI margins appropriate to a
specific study population, and to adapt end-of-study margins to observed characteristics of
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study populations. In the presence of known, measurable effect modifiers, these methods can
substantially reduce the undesirable effects of non-constancy. Our ongoing work includes
investigating ways to adapt NI margins during interim analyses in group sequential trials,
and appropriate ways to update samples sizes as result of adaptations to the margin and
hypotheses.
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Figure 1: PrEP effectiveness plotted against trial-level adherence, as measured by plasma
TDF, for all randomized trials of oral PrEP versus placebo where an objective adherence
measure was available. Circle sizes are proportional to the number of incident HIV infections
during the trial The fitted regression line and 95% confidence bounds (dashed lines) are
shown for men.
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Figure 2: Type I and type II error probabilities according to the true level of effectiveness
(% risk reduction vs. placebo) in the active-control arm. Rates are for a hypothetical NI
trial with NI-margin=1.3, effect size versus active-control=0.7, sample size = 110 events,
and planned active-control effectivess=50%.

19

Hosted by The Berkeley Electronic Press

Figure 3: Power for three adaptive-margin scenarios, according to the true level of effectiveness (% risk reduction vs. placebo) in the active-control arm, for a HIV prevention trials.
In scenario 1 both the null and alternative hypotheses are adapted accoring to pre-planned
levels of required benefit. In scenario 2 and 3 the level of required benefit is allowed to vary
according to observed study population characteristics. In scenario 3 the null hypothesis is
also required to preserve at least a (pre-specified) MCID over a hypothetical placebo arm.
Scenario 1 requires 204 observed events, while scenarios 2 and 3 require 371 observed events.
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